Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients

Background and objective: With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, the use of these treatments is under an ongoing change. We invest...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Mike Wenzel, Carolin Siech, Benedikt Hoeh, Florestan Koll, Clara Humke, Derya Tilki, Thomas Steuber, Markus Graefen, Séverine Banek, Luis A. Kluth, Felix K.H. Chun, Philipp Mandel
Format:	Artigo
Język:	Inglês
Wydane:	Elsevier 2024-08-01
Seria:	European Urology Open Science
Hasła przedmiotowe:	Metastatic prostate cancer Metastatic hormone-sensitive prostate cancer Metastatic castration-resistant prostate cancer Castration refractory De novo Recurrent
Dostęp online:	http://www.sciencedirect.com/science/article/pii/S2666168324004877
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!